1999; Nebes et al. 2003; Purcell et al. 1997; Reppermund et al. 2007]. Cognitive symptoms of diminished ability to concentrate and indecisiveness are part of the diagnostic classification of MDD according to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). MDD has been shown to affect cognitive domains of attention, concentration and memory. Inhibitors,research,lifescience,medical Other affected domains may include executive function, social cognitive performance, reasoning and problem solving. The extent to which these domains are affected in MDD is still

a matter of discussion among researchers [Austin et al. 2001; Gualtieri et al. 2006]. Given the centrality of cognitive dysfunction in MDD, it would follow that assessment of cognition is an important part of MDD disease evaluation. In actuality, little is known about physician perceptions of cognitive dysfunction in MDD or the clinical assessment of cognitive deficits in MDD in routine practice. Currently, there is no guidance for assessing Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical cognitive dysfunction in MDD. Additionally, little is known about the clinical use of cognitive assessment instruments. Given the lack of information on this issue, the purpose of the survey was to examine: (1) psychiatrists’ perceptions of cognitive dysfunction in MDD; (2) routine assessment of cognitive dysfunction in MDD patients in clinical practice;

and (3) use of cognitive dysfunction instruments in clinical assessment. Methodology Study design In March 2012, 786 psychiatrists from 6 countries were identified from a proprietary physicians list and were invited via email to participate in a cross-sectional, web-based survey. Psychiatrists Inhibitors,research,lifescience,medical from the US, France, Inhibitors,research,lifescience,medical Germany, Australia, Spain and Hong Kong were eligible

to complete the survey GF109203X provided they: (1) did not practice psychoanalysis; (2) prescribed drug therapies for their patients; (3) regularly assessed cognition in patients; (4) saw at least 50 patients per month with schizophrenia, MDD and bipolar disorder (BPD); and (5) obtained their medical degree between 1977 and 2009. All psychiatrists received the same set of questions. The survey link was disabled when the desired number of psychiatrists in each country completed the survey and psychiatrists were compensated by between €70 and tuclazepam €177 for their time depending on country. Survey components The survey was developed by Creativ-Ceutical and divided into three sections, each with multiple subparts. The first section of the questionnaire comprised questions for eligibility screening. The survey was terminated if any exclusion criteria were met. The second section consisted of sociodemographic questions regarding gender, country of residence, practice setting (rural or urban) and work environment (public, private or both).